Hepatic Insufficiency Clinical Trial
Official title:
A Phase 1 Study To Evaluate The Pharmacokinetics Of AG-013736 In Subjects With Impaired Hepatic Function
This study will evaluate the effects of mild and moderate impairment of hepatic function on the single-dose pharmacokinetics, safety and tolerability of AG-013736.
n/a
Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04097704 -
Pharmacogenetics Sampling of the CC-90007-CP-003 Study Cohort
|
||
| Completed |
NCT02161224 -
A Study to Investigate the Exposure and Safety and Tolerability of a Single Dose of FG-4592 in Subjects With Moderately Diminished Liver Function Compared to Those With Normal Liver Function
|
Phase 1 | |
| Completed |
NCT00929032 -
Liver Transplantation and Reticuloendothelial Clearance Capacity
|
N/A | |
| Completed |
NCT00509210 -
Study of Telaprevir in Subjects With Hepatic Impairment
|
Phase 1 | |
| Completed |
NCT02894385 -
Effect of Hepatic and Renal Impairment on the Pharmacokinetics, Safety and Tolerability of BAY1841788 (ODM-201)
|
Phase 1 | |
| Completed |
NCT03306667 -
Clinical Pharmacology of FYU-981 (Subjects With Hepatic Insufficiency)
|
Phase 1 | |
| Completed |
NCT04867941 -
A Study to Evaluate the Effect of Hepatic Insufficiency on the Pharmacokinetics (PK) of ACP-196
|
Phase 1 | |
| Terminated |
NCT02457702 -
Mitochondrial Function in Patients With Severe Liver Disease
|
N/A | |
| Completed |
NCT02090621 -
Extracorporeal Photopheresis After Liver Transplant
|
Phase 2 | |
| Completed |
NCT02249442 -
Study to Determine the Pharmacokinetics on TPV/r in Subjects With Mild and Moderate Hepatic Insufficiency
|
Phase 1 | |
| Completed |
NCT03341884 -
A Study of Ipatasertib in Participants With Mild, Moderate or Severe Hepatic Impairment Compared to Healthy Participants
|
Phase 1 | |
| Completed |
NCT01475136 -
A Study of LY2140023 in Hepatically-Impaired Participants
|
Phase 1 | |
| Completed |
NCT00969813 -
A Safety and Tolerability Study of CP-690,550 in Subjects With Hepatic Impairment and Normal Hepatic Function
|
Phase 1 | |
| Completed |
NCT00968591 -
Pharmacokinetics of Everolimus in Subjects With Hepatic Insufficiency
|
Phase 1 | |
| Completed |
NCT00931060 -
Effects of Branched-Chain Amino Acids on Muscle Ammonia Metabolism in Patients With Cirrhosis and Healthy Subjects
|
N/A | |
| Completed |
NCT00416702 -
Safety and Pharmacokinetics of Indacaterol in Healthy Subjects and Those With Impaired Liver Function
|
Phase 1 | |
| Completed |
NCT03968848 -
Investigate the Influence of Severe Hepatic Impairment on the Pharmacokinetics of Acalabrutinib and Its Metabolite
|
Phase 1 | |
| Completed |
NCT00314054 -
Study Evaluating the Safety of HCV-796 in Subjects With Liver Disease and in Healthy Adults
|
Phase 1 | |
| Completed |
NCT05731895 -
A Study to Test How Iclepertin is Taken up in the Blood of People With and Without Liver Problems
|
Phase 1 | |
| Completed |
NCT03842761 -
A Study to Test How Different Doses of BI 685509 Are Tolerated in Patients With Liver Problems
|
Phase 1 |